Metastatic Castration-resistant Prostate Cancer (mCRPC) research hub
7 indexed studies · 4 currently recruiting
- recruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
United States · Australia · Brazil - authorisedTherapeutic use (Phase IV)
Standard dosed abiraterone versus Therapeutic Drug Monitoring guided abiraterone dosing – The Adapt Abi trial
This study is looking at a common prostate cancer drug, abiraterone, to see if adjusting the dose based on regular blood tests can work better. The main goal is to find out if this approach can stop the cancer from growing for longer in men with advanced prostate cancer.
Netherlands - recruitingPHASE1
A Study of NX-1607 in Adults With Advanced Malignancies
This study is looking into a new treatment called NX-1607 for various advanced cancers, including ovarian, stomach, and lung cancer. It aims to see how safe the treatment is and if it can help fight the cancer, sometimes combined with another drug called Paclitaxel.
United States · United Kingdom - active not recruitingPHASE3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
This study is looking at a new combination treatment for advanced prostate cancer that has spread. It combines a new drug, Fuzuloparib, with standard treatments (abiraterone acetate and prednisone) to see if it can slow down cancer growth more effectively than the standard treatments alone.
United States · Australia · Belgium - recruitingPhase III
A Phase III randomized, open-label study of pasritamig (JNJ-78278343), a T-cell-redirecting agent targeting human kallikrein 2, with docetaxel versus docetaxel for metastatic castration-resistant prostate cancer
This study is testing a new drug, pasritamig, with an existing treatment for advanced prostate cancer called docetaxel. It aims to see if combining them works better than docetaxel alone for men whose cancer has spread and is resistant to hormone treatment.
United Kingdom · England · Scotland - recruitingPHASE1, PHASE2
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
This study, called PROMIZE, is looking at a new combination treatment for advanced prostate cancer that has spread and no longer responds to usual hormone therapy. It combines a standard prostate cancer drug (enzalutamide) with a mix of antibiotics to see if this new approach is safe and effective.
Switzerland · United Kingdom - recruitingPHASE1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
This study is testing a new drug, zanzalintinib, alone and with other medicines, for people with advanced cancers like kidney, prostate, and lung cancer. It's looking at safety and if the treatment shrinks tumours.
United States · Australia · Austria